The battle of the bulge is a losing proposition for many Americans. According to data derived from the most recent (2015–2016) National Health and Nutrition Examination Surveys (NHANES), the prevalence of obesity among U.S. adults was 39.8%.(1)
Visceral fat—the deeper belly fat that accumulates around the organs of the abdominal cavity, is linked to many health disorders that include heart disease, type 2 diabetes, high blood pressure (hypertension, and dementia.
With the evidence mounting on the associations between obesity, heart disease (CVD), and type 2 diabetes (T2D), to an increased risk for Alzheimer’s disease, an increased awareness of these associations and how it is all connected, now appears regularly in many popular news feeds. (more…)
While there is active research for more effective disease-modifying drugs* the lack of any significant breakthroughs in the treatment of the Alzheimer’s disease has propelled a paradigm shift away from focusing solely on a drug solution, to an inclusive prevention model that emphasizes risk reduction and prevention, which promises to attenuate the portentous global burden incurred by the disease.
Current prevalence estimates (2016) for late-onset Alzheimer’s disease (LOAD) in the United States (U.S.) is approximately 5.1 million.(1) By 2050 the projected prevalence of LOAD is expected to escalate to 13.8 million and a staggering 106.8 million worldwide.(2,3) Pharmacological treatments for LOAD such as cholinesterase inhibitors and NMDA receptor antagonists may slow its progression or attenuate specific molecular pathomechanisms associated with the disease process, but are not long term solutions or curative.